DrugPatentWatch Database Preview

Astrazeneca Pharms Company Profile

ASTRAZENECA PHARMS has nineteen approved drugs.

There are fifty-seven US patents protecting ASTRAZENECA PHARMS drugs.

There are one thousand two hundred and one patent family members on ASTRAZENECA PHARMS drugs in sixty-seven countries and one hundred and fifty supplementary protection certificates in nineteen countries.

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Pharms	IRESSA	gefitinib	TABLET;ORAL	206995-001	Jul 13, 2015		RX	Yes	Yes		Start Trial				Start Trial
Astrazeneca Pharms	DALIRESP	roflumilast	TABLET;ORAL	022522-002	Jan 23, 2018		RX	Yes	No	9,468,598	Start Trial	Y			Start Trial
Astrazeneca Pharms	EPANOVA	omega-3-carboxylic acids	CAPSULE;ORAL	205060-001	May 5, 2014		DISCN	Yes	No	9,050,308	Start Trial				Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca Pharms	NEXIUM	esomeprazole magnesium	CAPSULE, DELAYED REL PELLETS;ORAL	021153-002	Feb 20, 2001	7,411,070*PED	Start Trial
Astrazeneca Pharms	PRILOSEC OTC	omeprazole magnesium	TABLET, DELAYED RELEASE;ORAL	021229-001	Jun 20, 2003	5,753,265	Start Trial
Astrazeneca Pharms	PULMICORT RESPULES	budesonide	SUSPENSION;INHALATION	020929-001	Aug 8, 2000	6,899,099*PED	Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Delayed-release Capsules	20 mg	➤ Subscribe	2007-03-19
➤ Subscribe	Tablets	90 mg	➤ Subscribe	2015-07-20
➤ Subscribe	Tablets	500 mcg	➤ Subscribe	2015-03-02
➤ Subscribe	Tablets	50 mg, 150 mg and 400 mg	➤ Subscribe	2007-02-12
➤ Subscribe	Delayed-release	20 mg and 40 mg	➤ Subscribe	2005-08-05
➤ Subscribe	For Injection	20 mg/vial and 40 mg/vial	➤ Subscribe	2009-11-23
➤ Subscribe	Inhalation Suspension	1 mg/2 mL	➤ Subscribe	2010-05-28
➤ Subscribe	Delayed-release Tablets	20 mg	➤ Subscribe	2012-03-30
➤ Subscribe	Tablets	60 mg	➤ Subscribe	2015-09-30
➤ Subscribe	Tablets	25 mg	➤ Subscribe	2005-08-12
➤ Subscribe	Tablets	100 mg, 200 mg and 300 mg	➤ Subscribe	2006-02-21
➤ Subscribe	Delayed-release for Oral Suspension	2.5 mg and 5 mg	➤ Subscribe	2018-09-24
➤ Subscribe	Inhalation Suspension	0.25 mg/2 mL and 0.5 mg/2 mL	➤ Subscribe	2005-09-15

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1482932	C20190010 00281	Estonia	Start Trial	PRODUCT NAME: BINIMETINIIB;REG NO/DATE: EU/1/18/1315 24.09.2018
2673237	2019C/519	Belgium	Start Trial	PRODUCT NAME: LOKELMA - CYCLOSILICATE DE ZIRCONIUM SODIQUE; AUTHORISATION NUMBER AND DATE: EU/1/17/1173 20180326
1633724	596	Finland	Start Trial
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.